Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Impact of systemic imaging surveillance on survival from metastatic uveal melanoma
Ryan, Velvet Van, Zahrieh, David M. , Van Ryan, Velvet, Strand, Carrie , Churchill, Robert , Dalvin, Lauren A. , Dudek, Arkadiusz Z.

Melanoma Research | May 19, 2025 | Volume: 35 | Issue: 4 | Pages: 268-275

10.1097/cmr.0000000000001042 | PMID 40387899 Get It

The National Comprehensive Cancer Network (NCCN) recommended surveillance imaging intervals for uveal melanoma (UM) based on the risk of distant metastasis. The objective of this research is to evaluate if patients, treated at our tertiary cancer center, who had scans consistent with these guidelines, had improved overall survival (OS). This was a single-center, retrospective study of UM patients, who developed metastatic disease. Patients were grouped into risk-of-metastasis cohorts (low, medium, and high-risk) based on the UM NCCN guidelines v1.2023. The frequency of scans was reported within annual intervals for 5 years within the low-risk cohort and for 10 years within the medium-risk cohort, and within 6-month intervals for the first 5 years and then annually in years 6–10 within the high-risk cohort. Conditional landmark analyses were used to evaluate the relationship between OS and consistency with guidelines. Scan frequency was evaluated against socioeconomic status. Of the 740 UM patients identified (1997–2020), 110 experienced metastasis and comprised our analysis population (20 low-risk; 67 medium-risk; and 23 high-risk). The median time to death (95% confidence interval) from diagnosis of metastasis was similar between the low, medium, and high-risk cohorts at 1.2 (1.0, 2.0), 2.0 (1.7, 2.6), and 1.6 (1.3, 2.3) years, respectively. For each cohort, the OS results were similar between those who followed guidelines vs. not at each annual landmark time. Living in disadvantaged areas did not impact imaging frequency (all P > 0.05). Imaging at intervals outlined by the NCCN guidelines v1.2023 did not impact OS for patients who developed metastatic UM.
Strategies for Resection of Esophageal and Gastroesophageal Junction Submucosal Tumors
Alomari, Mohammad , Knewitz, Daniel , Larios, Rocio Castillo, Julien, Jamii St., Thomas, Mathew , Elli, Enrique F. , Bowers, Steven P. , Thomas, Mathew , Castillo Larios, Rocio, Thomas, Mathew

Journal of Laparoendoscopic & Advanced Surgical Techniques | May 19, 2025 | Volume: 35 | Issue: 7 | Pages: 564-569

10.1089/lap.2025.0079 | PMID 40388300 Get It

Efficacy of Hyperosmolar Dextrose Injection for Osgood–Schlatter Disease: A Systematic Review with Meta-Analysis
Rhim, Hye Chang , Bjork, Lori B., Shin, Jaehyung , DeLuca, Stephanie E., McCarron, Katelyn C., Jang, Ki-Mo , Ha, Chris, Ha, Chris Thuc , Jang, Ki-Mo , Ha, Chris , Park, Jewel , DeLuca, Stephanie E., McCarron, Katelyn

Diagnostics | May 19, 2025 | Volume: 15 | Issue: 10 | Pages: 1282

10.3390/diagnostics15101282 | PMID 40428275 Get It

Background/Objectives: Although Osgood–Schlatter disease (OSD) is often self-limiting following apophyseal closure, it may cause persistent symptoms into adulthood, affecting physical and functional activities. The purpose of this systematic review is to summarize the current evidence on the efficacy of hyperosmolar dextrose injection for patients with OSD unresponsive to conservative treatment. Methods: Multiple databases were searched for studies investigating the efficacy of hyperosmolar dextrose injection in patients with OSD. Two reviewers independently extracted data and evaluated the risk of bias. Meta-analyses were performed to compare hyperosmolar dextrose injection with placebo injections. Results: Four studies including three randomized controlled trials (RCTs) and one case series involving a total of 166 (162 males and 4 females) patients with 184 knees were included in this review. At three months, there was no significant difference in patient-reported improvement from baseline between hyperosmolar dextrose injection and placebo injections (standardized mean difference [SMD] = 1.92, 95% confidence interval [CI], −0.12 to 3.96; I2 = 96.2%). However, a meta-analysis of two RCTs including athletic pediatric patients found a pooled risk ratio of 2.11 (95% CI: 1.12 to 3.98, I2 = 30.73%) for pain-free return to sports at three months. In addition, at one year, a meta-analysis of two RCTs showed greater patient-reported improvement from baseline with hyperosmolar dextrose injection compared to placebo (SMD = 1.09, 95% CI, 0.62 to 1.56; I2= 0%). Conclusions: Based on the limited number of RCTs, although no improvement in patient-reported outcomes is seen at three months, hyperosmolar dextrose injection may safely facilitate a pain-free return to sports at three months and lead to patient-reported improvement at one year. However, further high-quality RCTs are needed to substantiate these findings.
Outpatient cardiovascular disease consultation wait times in the united states-mexico border regions
Abdelnabi, Mahmoud, Kanaan, Christopher, Mee, Xuan Ci , Lim, Ghee Kheng, Bcharah, George , Barry, Timothy, Lee, Justin Z, Farina, J M, Ayoub, Chadi , Lee, K L, Ibrahim, Ramzi, Griffith, Kevin N. , Pham, Hoang Nhat , Abdelnabi, Mahmoud , Arsanjani, Reza

European Journal of Preventive Cardiology | May 19, 2025 | Volume: 32 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwaf236.149 Get It

Abstract Background/Introduction Access to timely healthcare in disadvantaged areas remains essential to achieving equitable health outcomes, especially in regions facing structural and social vulnerabilities. Purpose To assess wait times for cardiovascular disease consultations in US-Mexico border regions compared to non-border regions among US Veterans. Methods This cross-sectional analysis included all veteran cardiovascular consultations referred through the Veterans Choice Program to community healthcare centers from 2014 to 2020. We obtained the average wait times in days for consultation approval, scheduling, completion, and total wait time from approval to consultation completion. All consultations were classified by county of residence as either within a US-Mexico border region or a non-border region, as per the La Paz Agreement. Multivariable linear regression analyses were performed to evaluate the impact of border status on average wait times. ARIMA modeling was completed to estimate forecasted wait times during the COVID-19 pandemic. Results A total of 485,158 consultations related to outpatient cardiovascular disease were retrieved from the VA Healthcare System. Amongst these, 461,696 of the consultations were placed in non-border regions whereas 23,462 consultations were placed in US-Mexico border regions. The most common consultation requests were made for general cardiology clinic (n=365,227), echocardiography (n=32,017), cardio-pulmonary rehabilitation (n=40,699), and cardiac stress testing (n=16,258). Wait times for cardiovascular disease consultations were not higher in US-Mexico border counties than in non-border regions. For electrophysiology consultations specifically, border counties exhibited significantly shorter total wait times (coeff = -10.81, p=0.008). Additionally, while the COVID-19 pandemic led to increased total wait times in non-border areas (Figure 1), total wait times in border regions remained stable during this period (Figure 2). Conclusions Our findings suggest that US-Mexico border region status does not result in longer wait times for cardiovascular disease consultations, with the exception of shorter wait times for electrophysiology services. This study provides important insights into the unique dynamics of healthcare access in structurally disadvantaged regions, highlighting that wait times are not a significant barrier to cardiovascular care in border areas, and emphasizes the need to consider regional differences in healthcare delivery policies.
Impact of sglt2 inhibitors on cardiovascular outcomes in patients with acute myocardial infarction
Ibrahim, Risqot Garba , Mee, Xuan Ci , Pham, Huyen Q., Abdelnabi, Mahmoud , Bcharah, George , Barry, Timothy, Fariña, Juliana, Ayoub, Chadi , Lee, K, Lim, G, Pham, H, Salih, Mustafa Abdalla M , Farina, J, Arsanjani, Reza

European Journal of Preventive Cardiology | May 19, 2025 | Volume: 32 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwaf236.239 Get It

Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) have emerged as a vital component in the management of heart failure (HF), demonstrating significant improvements in cardiac function. However, their impact on outcomes in patients with acute myocardial infarction (AMI) remains poorly characterized. This study aimed to evaluate the long-term outcomes of SGLT2-Is among patients with AMI. Methods We conducted a retrospective cohort study using data from the TriNetX Banner Health Network platform in the United States, including patients aged ≥18 years with AMI identified through ICD-10 codes. Patients were categorized into two cohorts based on SGLT2-I use. Propensity score matching (PSM) was performed to balance baseline demographics, comorbidities (e.g., hypertension, diabetes, chronic kidney disease, heart failure, and hyperlipidemia), and medication use (e.g., heart failure therapies, antiplatelet agents, anticoagulants). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were estimated for the following cardiovascular outcomes: acute HF hospitalizations, stroke, all-cause hospitalizations, recurrent AMI, cardiac arrest, and new-onset atrial fibrillation (AF). Kaplan-Meier analysis was completed to estimate survival probability from all-cause hospitalizations. Results After PSM, 2,440 patients were analyzed (1,220 SGLT2-I users; 1,220 non-users). Both cohorts had similar characteristics without any residual imbalance: mean age 67.7 years in the SGLT2-I group vs. 67.5 years in non-users, and both groups included 85.2% White and 33.6% female patients. Mean follow-up duration was 608 days for SGLT2-I users and 1,013.5 days for non-users. SGLT2-I use was associated with significantly lower rates of all-cause hospitalizations (RR: 0.712; 95% CI: 0.652–0.777), HF-related hospitalizations (RR: 0.878; 95% CI: 0.781–0.987), recurrent AMI (RR: 0.821; 95% CI: 0.703–0.959), and cardiac arrest (RR: 0.500; 95% CI: 0.345–0.725). No significant differences were observed in stroke (RR: 0.909; 95% CI: 0.702–1.178) or new-onset AF (RR: 0.889; 95% CI: 0.782–1.010) between the cohorts. Conclusions SGLT2-Is are associated with improved cardiovascular outcomes in patients with AMI, including reductions in all-cause and HF-related hospitalizations, recurrent AMI, and cardiac arrest. While these findings are hypothesis-generating, they emphasize the need for prospective clinical trials to confirm these results.Kaplan-Meier Analysis.
Meta-analysis of atherosclerosis in formerly pre-eclamptic women
Rooy, A De, Janssen, Emma B N J , Altintas, Sibel , Spaanderman, Marc E. A. , Jansen, Gerrit , Hof, Arnoud W.J. van ’t , Mihl, Casper , Kietselaer, Bas , Ghossein‐Doha, Chahinda

European Journal of Preventive Cardiology | May 19, 2025 | Volume: 32 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwaf236.463 Get It

Abstract Background Up to eight percent of pregnant women have pre-eclampsia. These women have an increased risk of future ischemic heart and cerebral disease. This warrants early cardiovascular risk management in early disease stages. This meta-analysis determines how the prevalence of subclinical atherosclerosis in women after pre-eclamptic compared to non-pre-eclamptic pregnancies changes over time. Methods A systematic search was used. Studies reporting the prevalence of systemic atherosclerosis using ultrasound or computed tomography in formerly pre-eclamptic and non-pre-eclamptic women were included. A random-effects meta-analysis provided overall odds ratio’s (OR (95% confidence interval (CI)) for the association between pre-eclampsia and the prevalence of atherosclerosis. Results Eleven articles could be included with a total of 13,217 participants. Maternal age ranged from 33 to 60 years. Within this age period, pooled OR of developing atherosclerosis after pre-eclampsia was 1.57 (95%CI 1.39-1.78). The pooled odds of developing atherosclerotic plaque after a pre-eclamptic versus a non-pre-eclamptic pregnancy increased gradually with age. The odds ratio was not significantly different in the 30-39 age group (OR 0.64 (95%CI 0.10-4.15)), but there was a statistically significantly increased odds of finding an atherosclerotic plaque in the 40-49 (OR 1.59 (95%CI 1.34-1.89)) and 50-60 age groups (OR 2.00 (95%CI 1.30-3.08)) after pre-eclamptic pregnancies compared to non-pre-eclamptic pregnancies. Conclusions Formerly pre-eclamptic women have earlier and more frequent atherosclerosis and occurs ten years earlier than in non-pre-eclamptic women. Targeted prevention strategies are required to prevent premature cardiovascular disease morbidity and mortality in formerly pre-eclamptic women.
1159 Insomnia and Perceived Cognitive Function in Solid Organ Transplant Recipients
Al-Saleh, Stacy , Attig, Stacie M., Mansour, Candace, Mahmoud, Jehan A., Conley, Samantha

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A500-A500

10.1093/sleep/zsaf090.1159 Get It

Abstract Introduction Solid organ transplant recipients experience high rates of cognitive impairment; however, little is known about what modifiable factors contribute to cognitive impairment after transplantation, limiting evidence-based treatment options. Insomnia is a sleep disorder that is associated with poor cognitive functioning in healthy adults and is amenable to interventions, but the relationship between insomnia and cognitive impairment after organ transplantation has not been explored. The purpose of this study was to identify relationships between insomnia, sleep characteristics, and perceived cognitive function after organ transplantation. Methods We conducted a descriptive, cross-sectional study of adult (>18 years) transplant recipients. We used the Insomnia Severity Index to measure insomnia, 10 days of continuous wrist actigraphy (Ambulatory Monitoring Inc. MicroMotionlogger) to measure sleep characteristics, and the PROMIS Cognitive Function to elicit perceived cognitive function. Descriptive statistics, Spearman’s Rho correlations, and Pearson’s correlations were used to describe relationships. Results We enrolled 34 participants [Mean age 62.5 years (SD 10.7), 64.7% (n=22) female, 85.3% (n=29) white, 17 liver/9 heart/8 kidney, average time since transplant 4.8 years (SD 4.2)]. 73.3% had clinically significant insomnia [mean ISI: 12.9 (SD 6.9)]. Sleep characteristics were obtained using actigraphy (mean duration: 7.03 hours [SD 1.28], onset latency: 9.16 min [SD 4.90], efficiency: 89.49% [SD 8.96], wake after sleep onset: 49.61 [SD 37.37]). Perceived cognitive function for the sample was worse than that of the general population, with a mean T-score of 45.21 (SD 11.44). Lower perceived cognitive function scores were significantly associated with younger age (rs = -.416, p=.016) and shorter time since transplant (rs =-.386, p=.024). Longer wake after sleep onset (rs =.347, p=.048) and lower sleep efficiency (rs=-.358, p=.041) were associated with lower perceived cognitive function. Lower perceived cognitive function was strongly associated with higher insomnia severity scores (r=.817, p=<.001). Conclusion Insomnia was common in our sample of transplant recipients and was strongly correlated with worse perceived cognitive function. Future research should incorporate objective measures of cognitive functioning and should consider insomnia treatment as a potential intervention to promote optimal cognitive functioning after organ transplantation. Support (if any) Mayo Clinic Center for Clinical and Translational Science.
1344 Assessing the Diagnostic Accuracy of LLM (ChatGPT-4) in Sleep Medicine Cases
Patel, Anshum , Delgado, Estefany Garces, Cheung, Joseph , Garces-Delgado, Estefany

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A578-A579

10.1093/sleep/zsaf090.1344 Get It

Abstract Introduction Large language models (LLMs), such as ChatGPT-4, have demonstrated promising potential as diagnostic tools across various medical disciplines. In sleep medicine, artificial intelligence tools are already used to analyze physiological sleep data and are being studied for their potential in phenotyping, endotyping, and predicting treatment responses. However, the effectiveness of LLMs in accurately diagnosing sleep disorders based on clinical history has not yet been studied. This study evaluates ChatGPT-4’s diagnostic performance using clinical vignettes. Methods Nineteen clinical cases were selected from the Case Book of Sleep Medicine, Third Edition (AASM, 2019). Each case included patient history, examination findings, and test results. The vignettes were input into ChatGPT-4 using the following standardized prompt: “Based on the provided case details, generate the top 5 differential diagnoses and identify the most likely final diagnosis: (copy and paste clinical vignette).” The model was tasked with generating both differential diagnoses and a final diagnosis for each case. The AI’s results were compared to reference diagnoses from the case book. Differential diagnoses were measured as the number of matches, and accuracy was reported as a percentage. Final diagnoses were scored as 0 (no match), 1 (partial match), or 2 (full match). Results The mean number of AI-generated differential diagnoses matching the AASM case differential diagnoses was 2.79 ± 0.71 (95% CI: 2.45–3.13). The mean accuracy percentage for differential diagnoses was 63.27% ± 15.61% (95% CI: 55.75%–70.79%), with scores ranging from 33.33% to 100%. For final diagnoses, ChatGPT-4 scored a total of 30 out of a possible 38, with a mean score was 1.58 ± 0.61 (95% CI: 1.29–1.87) out of 2, with 74% of cases achieving a full match. Performance was higher in cases with fewer differential diagnoses, whereas accuracy decreased in more complex cases. Conclusion ChatGPT-4 showed moderate to high accuracy in generating both differential and final diagnoses for sleep disorders. These findings suggest that AI could become a valuable clinical decision-support tool in sleep medicine. However, its inconsistent performance in complex cases highlights the need for further refinement and clinical testing. Support (if any)
Musculoskeletal Findings of the Major League Baseball Combine: A Description of the “Normal” Prospective Professional Baseball Player
Erickson, Brandon J. , D’Angelo, John , Ma, Kevin , Casey, Helen, Papp, Derek F. , Lund, Pamela, Chalmers, Peter N. , Camp, Christopher L. , Chalmers, Peter N , Hebert, Liz, Potter, Hollis G.

The American Journal of Sports Medicine | May 19, 2025 | Volume: 53 | Issue: 8 | Pages: 1826-1831

10.1177/03635465251339773 | PMID 40387901 Get It

Background: Major League Baseball (MLB) recently instituted a combine for their prospective players. Purpose/Hypothesis: The purpose of this study was to report initial epidemiological findings for both physical examination and imaging findings for the MLB Combine. It was hypothesized that most players would have no significant abnormal physical examination findings, but most would have abnormal findings on their shoulder and elbow magnetic resonance imaging (MRI) scans. Study Design: Descriptive epidemiology study. Methods: All players who attended the 2023 MLB Combine were included. History was taken and physical examination was performed by an MLB team physician, and MRI of the shoulder, elbow, cervical spine, and lumbar spine was performed on all players and read by 1 of 2 musculoskeletal radiologists. Physical examination notes and imaging reports were reviewed by the authors and recorded. Data were analyzed separately for pitchers and position players. Results: Overall, 219 players (112 pitchers [51%], 107 position players [49%]) were included. The mean age was 20.4 ± 1.5 years. The majority of players (95%) had no current pain or limitations; 54 players (25%) had a history of previous surgery. For pitchers, 18% underwent previous elbow surgery. With regard to MRI, >80% of pitchers had some abnormality within their ulnar collateral ligament (UCL), the majority of which was UCL scarring/remodeling. 70% of pitchers and 60% of position players had evidence of an olecranon osteophyte. Increased signal within the ulnar nerve was common in pitchers (40%) but rare in position players (4%). For the shoulder, 95% of pitchers and 93% of position players had some rotator cuff abnormality (often tendinosis within the supraspinatus and infraspinatus muscles). Also, 75% of pitchers had MRI evidence of a superior labrum anterior to posterior (SLAP) tear, while 24% of position players demonstrated this. Lumbar spine MRI showed that 47% of position players had a disk protrusion and 46% had a previous pars fracture. Conclusion: Most baseball players who participated in the 2023 MLB Combine had MRI evidence of rotator cuff abnormalities, and many showed evidence of an olecranon osteophyte. Eighteen percent of pitchers had a previous history of elbow surgery. The majority of pitchers had some abnormality within their UCL and evidence of a SLAP tear on MRI scans.
1147 Sleep Health and Disability Among Adults with Inflammatory Bowel Disease
Al-Saleh, Stacy , Schneekloth, Melanie, Kane, Sunanda V. , Conley, Samantha , Kamp, Kendra , Pinto, Melissa, Redeker, Nancy S.

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A495-A495

10.1093/sleep/zsaf090.1147 Get It

Abstract Introduction The majority of adults with inflammatory bowel disease (IBD) experience disability which is not fully explained by disease activity. Up to 80% of adults with IBD experience poor sleep health, which is associated with disability in other populations; however, the relationship between disability and sleep health among patients with IBD is largely unexamined. The purpose of this study was to compare the sleep health characteristics of those with and without IBD-related disability. Methods We recruited adults (18 to 59 years old) with IBD from a single academic medical center from 2022 to 2024. We measured disease activity using the Manitoba IBD Index and sleep using the PROMIS Sleep Disturbance and PROMIS Sleep-Related Impairment scales, the Insomnia Severity Index, and 14 days of wrist-worn actigraphy (Phillips Spectrum Plus, Phillips Respironics). We asked participants how many days they missed or had at least 50% reduced productivity in paid work or household work or missed leisure activities in the last 3 months related to their IBD. Disability was defined as missing six or more day over three months. We conducted bivariate analyses and logistic regressions to study associations. Results Among 83 adults with IBD [mean age = 40.4 years (SD 10.7), 59 (71.1%) were female, 56 (71.1%) had Crohn’s disease], and 49 (62.0%) had IBD-related disability. Patients with disability had more severe sleep disturbance (56.4 vs. 51.0, p <.001), sleep-related impairment (58.3 vs 50.3, p <.001), more severe insomnia (12.7 vs. 9.4, p =.029), and actigraph-measured higher wake after sleep onset (41.6 minutes vs. 34.0 minutes, p = 0.012) and lower sleep efficiency (85.1% vs. 87.9%, p = 0.032) compared to those without disability. After controlling for age and disease activity, sleep-related impairment (OR = 1.1, 95% CI 1.03, 1.15) was independently associated with disability. Conclusion Patients with IBD-related disability experience poor sleep health. Sleep related daytime impairment uniquely contributed to disability when controlling for disease activity. Sleep interventions need to be tested in adults with IBD to determine if they are effective at addressing disability in this population. Support (if any) Mayo Clinic Bonner Fund